Please login to the form below

Not currently logged in

Gilead shells out $375m for immuno-oncology deal with Arcus

Wide-ranging deal gives company access to bulk of biotech’s immuno-oncology pipeline


Gilead Sciences has accelerated its push into cancer with a wide-ranging deal with Arcus that gives it access to the bulk of the biotech’s immuno-oncology pipeline.

Arcus is claiming a $175m upfront payment under the  alliance, plus a $200m equity investment by Gilead, and could get up to $1.6bn in funding, opt-in and milestone payments of projects that progress as hoped.

The strategic alliance is cut from the same cloth as Gilead’s wide-ranging agreement with Galapapos last year, which added six clinical and 20 preclinical programmes to its pipeline but was substantially larger with an upfront fee of $3.95bn.

The format is similar however, with Gilead securing opt-in co-development and co-marketing rights to Arcus’ small-molecule and antibody-based cancer immunotherapies. Arcus currently has a clinical-stage pipeline of four immuno-oncology programmes, with another six compounds at the preclinical stage.

Arcus pipeline is headed by anti-TIGIT antibody AB154 which is in a phase 2 trial in first-line non-small-cell lung cancer (NSCLC) as a combination therapy with anti-PD1 antibody zimberelimab, (AB122) and small-molecule adenosine A2a/A2b receptor antagonist AB928.

The study ties into the emerging trend of testing immuno-oncology drugs in combination to try to enhance efficacy and reduce the proportion of non-responders to first-generation checkpoint inhibitors, and should generate results before the end of the year.

The TIGIT drug is also being tested in phase 1b/2 trials in other indications, including prostate, colorectal, pancreatic, triple negative breast and kidney cancers.

Meanwhile zimberelimab on its own is in a phase 1b study looking at cancers that aren’t address by the current crop of PD-1/PD-L1 inhibitors such as Merck & Co/MSD’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and as a combination therapy.

This second major pipeline-boosting deal under chief executive Daniel O’Day – at the helm for just over a year – comes as the company is still suffering from a dramatic decline in hepatitis C sales, increased pressure in its HIV franchise, and with a lot of work still to be done on its push to diversify into cancer and liver diseases.

CAR-T therapy for cancer Yescarta (axicabtagene ciloleucel) – acquired as part of its $12bn takeover of Kite – has been slow to build sales, and Gilead has also hit the buffers with its lead non-alcoholic steatohepatitis (NASH) therapy selonsertib after failed pivotal trials.

Arcus immediately expands Gilead’s immuno-oncology pipeline with rights to zimberelimab, and options on AB154 (for a $500m fee) as well as all other clinical candidates for payments ranging from $200m to $275m. That includes AB928 and AB680, an anti-CD73 small-molecule drug in phase 1 testing involving patients with pancreatic and gastrointestinal cancers.

Gilead also gets opt-in rights to all other programmes that emerge from Arcus' research portfolio over the next decade, upon payment of $150 million per programme.

Article by
Phil Taylor

28th May 2020

From: Research, Regulatory, Healthcare



PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs


Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

customer engagement 1
Building meaningful customer engagement through data-driven digital insights
Understanding the helpful insights that online HCP conversations can reveal...
4 ways to recruit Alzheimer’s disease patients for your clinical trial
What key things do you need to remember to reach patients living with Alzheimer’s disease?...
competitive intelligence
Integrating competitive intelligence into business development, licensing and M&A strategy
The advantages of partnering with a competitive intelligence or knowledge management team...